High incidence and poor prognosis of bone metastases in functioning small intestinal neuroendocrine tumors
BM are frequent in siNET, particularly in functioning tumors, and are associated with reduced survival. BM may initially be detectable only by functional imaging but becomes morphologically visible within less than 1.5 years. Antiresorptive therapy may reduce SREs. Whether adapting NET treatment algorithm for BM improves OS needs to be tested in clinical trials.
Authors
- Benedikt M. Schaarschmidt (ORCID: https://orcid.org/0000-0001-6331-7679)
- Harald Lahner (ORCID: https://orcid.org/0009-0008-0843-1565)
- Wolfgang P. Fendler (ORCID: https://orcid.org/0000-0002-5106-3584)
- Annie Mathew (ORCID: https://orcid.org/0000-0003-3233-5609)
- Dagmar Führer
- Pia Hauptmeier
Institutions
- European Neuroendocrine Tumor Society (DE)
- Essen University Hospital (DE)
- German Marine Research Consortium (DE)
- University of Duisburg-Essen (DE)
Publication Details
- Journal
- Frontiers in Endocrinology
- Published
- 2025-10-23
- DOI
- https://doi.org/10.3389/fendo.2025.1680209
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Universität Duisburg-Essen